A genetic mutation that promotes cancer development blocks the normal sorting of a protein called “Argonaute 2.”

Investigators at Vanderbilt University Medical Center have published research regarding an important feature of colorectal cancer (CRC) that could eventually lead to the development of non-invasive means of monitoring cancer progression. After lung cancer, CRC is the second-most lethal cancer in the United States.

Studies of the molecular complex that helps build specialized cellular surfaces could shed light on the mechanisms underlying a genetic deaf-blindness syndrome accompanied by intestinal disease.

A family of proteins with critical roles in cell division, synaptic transmission and cell migration don’t all function the way scientists thought they did, according to two new studies led by Vanderbilt researchers.

Vanderbilt researchers have developed a new method to study cell signaling networks at single-cell resolution.

Vanderbilt’s Ian Macara, Ph.D., has won an Outstanding Investigator Award from the National Cancer Institute (NCI) — nearly $6.6 million over seven years — to support the “unusual potential” of his research, which seeks to understand and predict cancer cell “behavior.”

Ian Macara, Ph.D., professor and chair of the Department of Cell and Developmental Biology, recently returned from Scotland, where he received this year’s Colin Thomson Memorial Medal for his contributions to cancer research.